Login to Your Account



Pharma: clinic roundup


Wednesday, May 7, 2014

Novartis AG, of Basel, Switzerland, presented results at the European Congress of Endocrinology in Wroclaw, Poland, from a pivotal phase III study of Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription